Cytochroma Inc.

330 Cochrane Drive
L3R 8E4 Markham
Canada

Contact

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of Vitamin D insufficiency and SHPT associated with CKD. The Company's Vitamin D-based therapeutics are designed to safely and effectively treat pre-dialysis and dialysis CKD patients. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia.

Product portfolio of Cytochroma

Product portfolio

Show all

News about Cytochroma

27-May-2010 | research and development

Cytochroma announces positive Phase 1/2 results for CTAP101 capsules in non-dialysis chronic kidney disease patients

Cytochroma announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated ...

Read news

30-Nov-2009 | people

Cytochroma Announces Appointment of Peter Moldt to Board of Directors

Cytochroma announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative ...

Read news

19-Oct-2009 | people

Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board

Cytochroma announced that it has appointed John Cunningham, CVO, BM BCh, DM, FRCP, to the Company's Scientific Advisory Board. Dr. Cunningham is Professor ...

Read news

05-May-2008 | business & finance

Cytochroma opens U.S. headquarters in Illinois

Cytochroma announced the opening of its U.S. headquarters in Bannockburn, Illinois, located in the greater Chicago area. The site will serve as the Company ...

Read news

Show more news about Cytochroma